Saturday, 3 October 2026European Markets

ATOS Stock 16.32% Up On Thursday

Loading stream...

(vianews) - the market ended the session with atos (ato.pa) jumping 16.32% to €0.85 on thursday, following the last session's upward trend. cac 40 jumped 0.71% to €7,627.13, following the last session's upward trend on what was a somewhat bullish trend exchanging session today.

about atos

atos se provides digital transformation solutions and services worldwide. it offers advanced computing solutions; analytics, artificial intelligence, and automation solutions; cloud solutions; customer journey analytics and digital customer experience; decarbonization solutions; digital consulting; digital workplace solutions; edge computing and internet of things solutions; and modern applications and platforms. the company also provides advance detection and response, data protection and governance, digital workplace security, iot and ot security, trusted digital identities, and cybersecurity solutions; and infrastructure and foundation services. it serves financial services and insurance, healthcare and life sciences, manufacturing, public sector and defense, resources and services, and telecommunication and media industries. the company was incorporated in 1982 and is headquartered in bezons, france.

earnings per share

as for profitability, atos has a trailing twelve months eps of €-31.04.

volatility

atos's last week, last month's, and last quarter's current intraday variation average was a negative 1.12%, a negative 2.48%, and a positive 7.88%.

atos's highest amplitude of average volatility was 6.55% (last week), 13.96% (last month), and 7.88% (last quarter).

more news about atos (ato.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com